Company intelligence
NonExomics
Redefining Medicinal Genomics
About NonExomics
NonExomics, Inc is a scientists-led company that has pioneered the discovery process of the new wave of targets from the so-called Dark Genome. Over the last 8 years, we have meticulously developed AI-based algorithms deployed on the patient data at a population scale, to discover over 250,000 new proteins and investigated their disruptions in over 1365 human diseases. We have performed extensive in silico and experimental validation on these new targets to develop them as diagnostics and therapeutics. Our target portfolio serves as a parallel universe in drug discovery that is ripe to be challenged by the available therapeutic modalities in various diseases. We welcome opportunities to collaborate with other partners in challenging these newly-found genes using small molecules, antisense oligos, antibodies, gene therapy, etc.
Verified activity
Signals from NonExomics
2 published signals
Research & Knowledge
NonExomics published a new co-authored article for BioPharmaTrend.com detailing the story of dark proteomes and drug targets in cancer and other diseases.
Reported by NonExomics
Research & Knowledge
NonExomics traced how the field got here from systematic evidence back in 2014 to the question of which thousands of detected proteins should be drug targets.
Reported by Sudhakaran Prabakaran, Ph.D., FRSB